Biotechnology
China-Based Ivy Capital Invests in Betagenon's Clinical Stage AMPK Activator Program
STOCKHOLM, Jan. 20, 2020 /PRNewswire/ -- Balticgruppen Bio, the Umea based Biotech company focused on development of AMPK activator compounds, operating under the trademark Betagenon, has closed a funding round withChina based asset management firm Ivy Capital granting the company 3 MUSD of fundi...
2020-01-20 11:14
911
QBiotics receives first registration for tigilanol tiglate with European Medicines Agency approval of Stelfonta(R)
* STELFONTA® (tigilanol tiglate) approved by the European Medicines Agency (EMA), making it the first pharmaceutical treatment available for all grades of canine non-metastatic mast cell tumours (MCT)[1] * The approval marks the first registration of QBiotic's, lead compound tigilanol tiglate...
2020-01-20 07:00
3258
Innovent Out-Licenses Commercial Rights for Avastin® Biosimilar to Coherus BioSciences in the United States and Canada
SUZHOU, China, Jan. 14, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or the "Company") (HKEX: 01801), a biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today announced tha...
2020-01-14 08:00
15622
Evolution 2.0 Prize: Unprecedented $10 Million Offered To Replicate Cellular Evolution
CHICAGO, Jan. 14, 2020 /PRNewswire/ -- An incentive prize ten times the size of the Nobel – believed to be the largest single award ever in basic science – is being offered to the person or team solving the largest mystery in history: how genetic code inside cells got there, and how cells intent...
2020-01-14 03:23
1094
Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related Macular degeneration (AMD) and Diabetic Macular Oedema (DMO)
The program, facilitated by Johnson & Johnson Innovation, has the potential to improve the treatment of patients with retinal vascular diseases and transform the lives of those suffering from vision loss. CAMBRIDGE, England, Jan. 13, 2020 /PRNewswire/ -- Exonate, an early stage biotechnology com...
2020-01-13 16:00
1101
Nanoform Appoints Head of US Sales
HELSINKI, Jan. 13, 2020 /PRNewswire/ -- Nanoform, an innovative nanoparticle medicine enabling company, has appointedSally Langa as Head of US Sales. The new role will enable Nanoform to continue its rapid growth with a strengthened presence in the US market. As Head of US Sales, Sally Langa wil...
2020-01-13 15:21
971
FHA-Food & Beverage spotlights tech innovation and industry transformation in new FoodTech Zone
SINGAPORE, Jan. 9, 2020 /PRNewswire/ -- From novel farming methods to connected
kitchens, thetechnological and investment potential in the food tech space
2020-01-09 12:03
3358
Publication of a Toxicological Study: A Milestone for Jennewein Biotechnologie for the GRAS Approval of the HMO-mix
RHEINBREITBACH, Germany, Jan. 9, 2020 /PRNewswire/ -- Jennewein Biotechnology announces another milestone in the worldwide approval of a new product generation, the "HMO-Mix." The data of the toxicological study, with the title "A Safety Evaluation of Mixed Human Milk Oligosaccharides in Rats," w...
2020-01-09 02:26
2458
Waters Corporation Lauded by Frost & Sullivan for Developing the First Truly Smart Mass Spectrometer, the BioAccord LC-MS System
The system was designed to enhance productivity, positioning the user to acquire and process data with a purpose-built LC-MS platform SANTA CLARA, California, Jan. 8, 2020 /PRNewswire/ -- Based on its analysis of the global biopharmaceutical analytical instrumentation market, Frost & Sullivan ...
2020-01-08 21:30
6274
Hummingbird Bioscience Publishes Preclinical Data Demonstrating Efficacy of HMBD-001 in HER3 Driven Cancers
* HER3 activation is implicated in tumor progression and in acquired resistance to EGFR and HER2 therapies * Study, published in Molecular Cancer Therapeutics, found HMBD-001 to be able to uniquely block HER3 dimerization interface and potently inhibit tumor growth SINGAPORE, Jan. 8, 2020 /PR...
2020-01-08 10:40
806
Continued Success of Novoheart to Receive R&D Grants: Innovation Technology Fund for Developing Smart Cardiac Screening Technologies
* Grant will fund advanced R&D and incorporation of artificial intelligence (AI) technology to accelerate drug development using Novoheart's bio-engineered human heart chambers and tissues * Potential advancements expected to increase scale and capabilities of Novoheart's MyHeart™ Platform an...
2020-01-07 17:39
2674
Mundipharma Announces Exclusive Deal for Biosolution's CartiLife(R) in South Korea
SINGAPORE, Jan. 7, 2020 /PRNewswire/ -- Mundipharma has announced today that it has sealed an exclusive sales agreement with Biosolution Co., Ltd, a Korea-based leader in cell-based biotechnology, to market and distribute its fourth-generation autologous chondrocyte implantation product, CartiLif...
2020-01-07 11:37
2936
genOway and Merck Strengthen CRISPR/Cas9 Strategic Alliance by Extending Their Partnership to All Animal Cell Models
genOway acquires additional rights to develop all animal cell models using the CRISPR/Cas9 system LYON, France, Jan. 7, 2020 /PRNewswire/ -- genOway, a public company and leader in developing genetically modified research models, today announced an important milestone in extending its strategic ...
2020-01-07 09:00
2842
Japanese Clinical Study of DiscGenics' Cell Therapy for Disc Degeneration Passes Initial Safety Review
SALT LAKE CITY and TOKYO, Jan. 7, 2020 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that IDCT has p...
2020-01-07 08:00
1402
BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Not intended for US-, Canada- and UK-based media - At the planned interim analysis, Phase III JAVELIN Bladder 100 study met the primary endpoint of prolonging overall survival (OS) as a first-line maintenance treatment versus standard of care - BAVENCIO is the first immunotherapy to signifi...
2020-01-06 20:00
4711
Yisheng Biopharma and Tavotek Biotherapeutics Announce Strategic Research Alliance for Development of YS-ON-001/002 and Tavo-301/303 Combination Therapy for Cancer Treatment
GAITHERSBURG, Md. and AMBLER, Pa., Jan. 6, 2020 /PRNewswire/ -- Yisheng Biopharma Co., Ltd. ("Yisheng Biopharma"), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, and Tavotek Biotherapeutics, a biotech c...
2020-01-06 09:00
2935
WuXi Biologics Congratulates OncoImmune on FDA Clearance of IND Application for Next Generation anti-CTLA-4 Antibody ONC-392
SHANGHAI, Jan. 2, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, congratulates its partner OncoImmune on the U.S. Food and Drug ...
2020-01-02 08:08
2580
Focusing on Cutting-edge Biopharmaceutical Technologies, Boosting the Industry to Achieve Innovation and Development
SHANGHAI, Dec. 25, 2019 /PRNewswire/ -- To seize the ever-changing opportunities in the new era and to meet the ever-growing market demands, the annual gala of the biopharmaceutical industry---bioLIVE China 2020, will be held again at Hall W4 in the SNIEC onJune 22-24, 2020. The exhibition, co-l...
2019-12-25 12:55
2825
EpiVax Announces Record Year for Growth in 2019 and Sets New Milestones for 2020
PROVIDENCE, Rhode Island, Dec. 24, 2019 /PRNewswire/ -- EpiVax ("EpiVax, Inc.") continues its record-breaking performance and growth in personnel in 2019 while identifying new milestones to aspire to in 2020. The Business Development team closed 15% more contracts over 2018 and acquired two ne...
2019-12-24 16:35
2036
WuXi Biologics Receives "Special Award to Investors in Ireland" from Asia Matters
DUBLIN, Dec. 23, 2019 /PRNewswire/ -- December 23, 2019 – WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has received the "Special Awa...
2019-12-23 16:26
2225
Week's Top Stories
Most Reposted
Singapore-based video streaming provider teams up with renowned celebrity platform to provide much-needed boost for brands
[Picked up by 323 media titles]
2024-09-13 17:12
HS HYOSUNG Unveils New CI and Vision, Embracing "Star" and "Tree" Symbolism
[Picked up by 313 media titles]
2024-09-11 20:27FETC International's MD Dr. Y.C. Chang Honored with the "Master Entrepreneur Award" at APEA 2024
[Picked up by 306 media titles]
2024-09-16 11:50
VinCSS, A Vietnamese Startup, Becomes the World's First Company to Secure FIDO Device Onboarding (FDO) Certificates
[Picked up by 298 media titles]
2024-09-11 15:20
NATIONAL ENERGY AWARDS 2024 SHOWCASES MALAYSIA'S COMMITMENT TO ENERGY MANAGEMENT, ENERGY EFFICIENCY AND RENEWABLE ENERGY SOLUTIONS
[Picked up by 287 media titles]
2024-09-13 15:00
Most Read
VinCSS, A Vietnamese Startup, Becomes the World's First Company to Secure FIDO Device Onboarding (FDO) Certificates
2024-09-11 15:20
11481
HS HYOSUNG Unveils New CI and Vision, Embracing "Star" and "Tree" Symbolism
2024-09-11 20:27
11251
Mushiny Establishes Subsidiary in Japan and Showcases New Products at LTT Expo Empowering Local Partners: Mushiny's Deep Collaboration to Revolutionize the Future of Logistics
2024-09-10 17:12
7300
Circles and e& international mark one-year success of JV & digital telco leadership
2024-09-10 15:00
6771
InCorp Global Wins "Sustainability Champion" Award at PrimeGlobal's Golden Globes
2024-09-10 17:00
6748